Immunogenic cell death and emission of damps: calreticulin and ATP by Krysko, Dmitri
Volume 2 • Issue 4 • 1000e118
J Nanomed Biotherapeut Discov
ISSN:2155-983X JNBD an open access journal 
Editorial Open Access
Nanomedicine & Biotherapeutic 
Discovery
Krysko, J Nanomed Biotherapeut Discov 2012, 2:4
http://dx.doi.org/10.4172/2155-983X.1000e118
Abbreviations: ATP: Adenosine Triphosphate; CRT: Calreticulin; 
DAMP: Damage-Associated Molecular Pattern; MYD88; Myeloid 
Differentiation Primary Response Gene 88; NLR: The Nucleotide-
Binding Oligomerization Domain (NOD)-Like Receptor; PRR: 
Pattern-Recognition Receptor; RLR: RIG-I-Like Receptor; TLR: Toll-
Like Receptor
The ‘danger theory’ was first proposed by Polly Matzinger in 
1994. This theory states that the immune system can distinguish 
self from non-self and dangerous from innocuous signals [1]. 
This theory has become widely accepted in recent years, especially 
with the formulation of immunogenic cell death (ICD) concept 
[2]. Immunogenic characteristics of ICD are mediated mainly by 
molecules called ‘Damage-Associated Molecular Patterns’ (DAMPs). 
These are intracellular molecules normally hidden within live cells, but 
they acquire immunostimulatory properties upon exposure/release/
secretion by damaged/dying cells. 
It was recently reported that only certain agents (e.g. anthracyclines, 
γ-irradiation and hypericin based photodynamic therapy) induce 
active emission of DAMPs by dying apoptotic cells, and this property 
determines the efficacy of anti-cancer therapy in the experimental 
tumor prophylactic vaccination model [3-5]. These studies have 
shown that surface exposure of calreticulin (CRT), a soluble protein 
normally located in the lumen of the endoplasmic reticulum, on tumor 
cells undergoing ICD in response to certain chemotherapeutics (e.g. 
anthracyclines) facilities their engulfment by dendritic cells (DCs). This 
leads to tumor-antigen presentation and tumor-specific cytotoxic-T 
lymphocyte (CTL) responses [3]. It is important to stress that the 
molecular signaling pathways involved in CRT exposure are strongly 
dependent on the ICD inducer [4,5]. Another DAMP shown to be 
actively secreted from cells undergoing ICD is ATP [5,6]. Secretion of 
ATP, which occurs very early during apoptosis, is also tightly regulated 
by molecular program(s) [5]. 
Upon their exposure or release by dying cells, DAMPs interact with 
membrane-bound or vesicular pattern-recognition receptors (PRRs), 
including Toll-like receptors (TLRs), purinergic receptors, NOD-like 
receptors (NLRs) and RIG-I-like receptors (RLRs) [7,8]. For example, it 
has been shown that extracellular ATP released from cells undergoing 
ICD activates purinergic P2X7 receptors on DCs. This activates the 
NALP3–ASC–inflammasome and drives the secretion of IL-1β, which 
is required for the polarization of interferon-γ (IFN-γ)-producing 
CD8+ T cells and for the immune response to tumor cells [9]. We 
also recently demonstrated that the TLR-2/TLR-9-MyD88 signaling 
pathways have a central role in initiating the acute inflammatory 
response to cells undergoing ICD [10]. 
Substantial progress has been made over the past few years in 
identifying the DAMPs exposed/released/secreted during ICD and 
the molecular mechanisms of their emission and recognition by 
the innate and adaptive immune systems. Indeed, nanoparticles 
and their applications in biomedicine and medicine has become an 
extensive area of research [11]. It is important to analyze whether 
nanopartciles act as DAMPs, whether they can be designed with unique 
immunomodulatory properties (dependent on size, shape, surface 
charge and solubility), and if they can instigate different immunological 
responses. These immunomodulatory properties might be specific for 
a precise physical type of engineered nanoparticle, and further studies 
are required to identify and analyze nanoparticle-associated molecular 
patterns (NAMPs) [12]. Since nanoparticles are also designed to target 
tumors in vivo and are intended for use as therapeutic drug carriers 
[11], it will be important to analyze whether drugs delivered in 
nanoparticles will have increased (or changed) immunogenic potential 
in terms of induction of ICD and emission of DAMPs. 
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